coda noninvasive system Search Results


plethysmographic and noninvasive device coda standard monitor  (emka TECHNOLOGIES S A S)
90
emka TECHNOLOGIES S A S plethysmographic and noninvasive device coda standard monitor
Plethysmographic And Noninvasive Device Coda Standard Monitor, supplied by emka TECHNOLOGIES S A S, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/coda+noninvasive+system/plethysmographic+and+noninvasive+device+coda+standard+monitor/pmc04054801-37-12-17
Average 90 stars, based on 1 article reviews
plethysmographic and noninvasive device coda standard monitor - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
kent coda noninvasive blood pressure monitor  (emka TECHNOLOGIES S A S)
90
emka TECHNOLOGIES S A S kent coda noninvasive blood pressure monitor
Kent Coda Noninvasive Blood Pressure Monitor, supplied by emka TECHNOLOGIES S A S, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/coda+noninvasive+system/kent+coda+noninvasive+blood+pressure+monitor/10__1097_slash_ccm__0000000000000624-97-12-18
Average 90 stars, based on 1 article reviews
kent coda noninvasive blood pressure monitor - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
noninvasive tail cuff system coda for rodents  (emka TECHNOLOGIES S A S)
90
emka TECHNOLOGIES S A S noninvasive tail cuff system coda for rodents
(A) Schematic overview of the Nppa locus, including the natural antisense transcript Gm13054 on chromosome 4 (GRCm38/mm10 assembly). Arrows indicate direction of transcription. (B) Nppa-as and (C) Nppa expression in HL-1 cells transfected with different GapmeR designs and negative control, as measured by qRT-PCR. Expression is presented relative to Gapdh and normalized to the mean of the control group. Results are based on 3 separate experiments with 3 replicates in each group. Kruskal-Wallis was used to test the effect of each GapmeR design compared to the negative control. ***P < 0.001, **P < 0.01 after adjustment for multiple comparisons using Dunn’s test. (D) Nppa-as and (E) Nppa expression in atrial tissue of mice injected subcutaneously with 6.25, 12.5, or 25 mg/kg of GapmeR5 or 25 mg/kg of negative control GapmeR for 48 hours (n = 5–13 per group). Kruskal-Wallis was used to test the difference between animals treated with negative control and each of the G5 doses, as well as within G5 treatment groups. ***P < 0.001, *P < 0.05 after adjusting for multiple comparisons using Dunn’s test. (F) Plasma concentration of Anp in the saphenous vein of mice before and 48 hours after injection of the different Gapmer5 doses or 25 mg/kg of negative control GapmeR, as measured by ELISA (n = 5–13 per group). Repeated-measures 2-way ANOVA was used to test the difference before and after treatment in each group. *P < 0.05, **P < 0.01 after adjusting for multiple comparisons using Dunn’s test. (G) Systolic (SBP) and diastolic blood pressure (DBP) in mice before and 48 hours after GapmeR injections measured using a <t>noninvasive</t> <t>tail</t> <t>cuff</t> method (n = 5/group). Repeated-measures 2-way ANOVA was used to test for differences within groups. *P < 0.05 after adjusting for multiple comparisons using Dunn’s test. (H) Correlation of G5 dose with SBP and DBP in treated animals. Pearson’s correlation coefficient and P value are shown. (I) Kidney cGMP in each treatment group (n = 5/group) as measured by ELISA. Kruskal-Wallis was used to test the effect of each of the G5 doses compared to negative control GapmeR. *P < 0.05 after adjustment for multiple comparisons using Dunn’s test. For all graphs, mean and standard deviation are shown.
Noninvasive Tail Cuff System Coda For Rodents, supplied by emka TECHNOLOGIES S A S, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/coda+noninvasive+system/noninvasive+tail+cuff+system+coda+for+rodents/pmc06795498-558-1-8
Average 90 stars, based on 1 article reviews
noninvasive tail cuff system coda for rodents - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
coda ht4 noninvasive blood pressure system  (Kent Scientific Corp)
86
Kent Scientific Corp coda ht4 noninvasive blood pressure system
(A) Schematic overview of the Nppa locus, including the natural antisense transcript Gm13054 on chromosome 4 (GRCm38/mm10 assembly). Arrows indicate direction of transcription. (B) Nppa-as and (C) Nppa expression in HL-1 cells transfected with different GapmeR designs and negative control, as measured by qRT-PCR. Expression is presented relative to Gapdh and normalized to the mean of the control group. Results are based on 3 separate experiments with 3 replicates in each group. Kruskal-Wallis was used to test the effect of each GapmeR design compared to the negative control. ***P < 0.001, **P < 0.01 after adjustment for multiple comparisons using Dunn’s test. (D) Nppa-as and (E) Nppa expression in atrial tissue of mice injected subcutaneously with 6.25, 12.5, or 25 mg/kg of GapmeR5 or 25 mg/kg of negative control GapmeR for 48 hours (n = 5–13 per group). Kruskal-Wallis was used to test the difference between animals treated with negative control and each of the G5 doses, as well as within G5 treatment groups. ***P < 0.001, *P < 0.05 after adjusting for multiple comparisons using Dunn’s test. (F) Plasma concentration of Anp in the saphenous vein of mice before and 48 hours after injection of the different Gapmer5 doses or 25 mg/kg of negative control GapmeR, as measured by ELISA (n = 5–13 per group). Repeated-measures 2-way ANOVA was used to test the difference before and after treatment in each group. *P < 0.05, **P < 0.01 after adjusting for multiple comparisons using Dunn’s test. (G) Systolic (SBP) and diastolic blood pressure (DBP) in mice before and 48 hours after GapmeR injections measured using a <t>noninvasive</t> <t>tail</t> <t>cuff</t> method (n = 5/group). Repeated-measures 2-way ANOVA was used to test for differences within groups. *P < 0.05 after adjusting for multiple comparisons using Dunn’s test. (H) Correlation of G5 dose with SBP and DBP in treated animals. Pearson’s correlation coefficient and P value are shown. (I) Kidney cGMP in each treatment group (n = 5/group) as measured by ELISA. Kruskal-Wallis was used to test the effect of each of the G5 doses compared to negative control GapmeR. *P < 0.05 after adjustment for multiple comparisons using Dunn’s test. For all graphs, mean and standard deviation are shown.
Coda Ht4 Noninvasive Blood Pressure System, supplied by Kent Scientific Corp, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/coda+noninvasive+system/blood+coda+ht4+noninvasive+pressure+system/pmc12545229-308-5-10
Average 86 stars, based on 1 article reviews
coda ht4 noninvasive blood pressure system - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
noninvasive bp system  (Kent Scientific Corp)
86
Kent Scientific Corp noninvasive bp system
(A) Schematic overview of the Nppa locus, including the natural antisense transcript Gm13054 on chromosome 4 (GRCm38/mm10 assembly). Arrows indicate direction of transcription. (B) Nppa-as and (C) Nppa expression in HL-1 cells transfected with different GapmeR designs and negative control, as measured by qRT-PCR. Expression is presented relative to Gapdh and normalized to the mean of the control group. Results are based on 3 separate experiments with 3 replicates in each group. Kruskal-Wallis was used to test the effect of each GapmeR design compared to the negative control. ***P < 0.001, **P < 0.01 after adjustment for multiple comparisons using Dunn’s test. (D) Nppa-as and (E) Nppa expression in atrial tissue of mice injected subcutaneously with 6.25, 12.5, or 25 mg/kg of GapmeR5 or 25 mg/kg of negative control GapmeR for 48 hours (n = 5–13 per group). Kruskal-Wallis was used to test the difference between animals treated with negative control and each of the G5 doses, as well as within G5 treatment groups. ***P < 0.001, *P < 0.05 after adjusting for multiple comparisons using Dunn’s test. (F) Plasma concentration of Anp in the saphenous vein of mice before and 48 hours after injection of the different Gapmer5 doses or 25 mg/kg of negative control GapmeR, as measured by ELISA (n = 5–13 per group). Repeated-measures 2-way ANOVA was used to test the difference before and after treatment in each group. *P < 0.05, **P < 0.01 after adjusting for multiple comparisons using Dunn’s test. (G) Systolic (SBP) and diastolic blood pressure (DBP) in mice before and 48 hours after GapmeR injections measured using a <t>noninvasive</t> <t>tail</t> <t>cuff</t> method (n = 5/group). Repeated-measures 2-way ANOVA was used to test for differences within groups. *P < 0.05 after adjusting for multiple comparisons using Dunn’s test. (H) Correlation of G5 dose with SBP and DBP in treated animals. Pearson’s correlation coefficient and P value are shown. (I) Kidney cGMP in each treatment group (n = 5/group) as measured by ELISA. Kruskal-Wallis was used to test the effect of each of the G5 doses compared to negative control GapmeR. *P < 0.05 after adjustment for multiple comparisons using Dunn’s test. For all graphs, mean and standard deviation are shown.
Noninvasive Bp System, supplied by Kent Scientific Corp, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/coda+noninvasive+system/bp+coda+high+noninvasive+system+throughput/pm41844569-389-7-18
Average 86 stars, based on 1 article reviews
noninvasive bp system - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
coda mouse bp system  (Kent Scientific Corp)
86
Kent Scientific Corp coda mouse bp system
(A) Schematic overview of the Nppa locus, including the natural antisense transcript Gm13054 on chromosome 4 (GRCm38/mm10 assembly). Arrows indicate direction of transcription. (B) Nppa-as and (C) Nppa expression in HL-1 cells transfected with different GapmeR designs and negative control, as measured by qRT-PCR. Expression is presented relative to Gapdh and normalized to the mean of the control group. Results are based on 3 separate experiments with 3 replicates in each group. Kruskal-Wallis was used to test the effect of each GapmeR design compared to the negative control. ***P < 0.001, **P < 0.01 after adjustment for multiple comparisons using Dunn’s test. (D) Nppa-as and (E) Nppa expression in atrial tissue of mice injected subcutaneously with 6.25, 12.5, or 25 mg/kg of GapmeR5 or 25 mg/kg of negative control GapmeR for 48 hours (n = 5–13 per group). Kruskal-Wallis was used to test the difference between animals treated with negative control and each of the G5 doses, as well as within G5 treatment groups. ***P < 0.001, *P < 0.05 after adjusting for multiple comparisons using Dunn’s test. (F) Plasma concentration of Anp in the saphenous vein of mice before and 48 hours after injection of the different Gapmer5 doses or 25 mg/kg of negative control GapmeR, as measured by ELISA (n = 5–13 per group). Repeated-measures 2-way ANOVA was used to test the difference before and after treatment in each group. *P < 0.05, **P < 0.01 after adjusting for multiple comparisons using Dunn’s test. (G) Systolic (SBP) and diastolic blood pressure (DBP) in mice before and 48 hours after GapmeR injections measured using a <t>noninvasive</t> <t>tail</t> <t>cuff</t> method (n = 5/group). Repeated-measures 2-way ANOVA was used to test for differences within groups. *P < 0.05 after adjusting for multiple comparisons using Dunn’s test. (H) Correlation of G5 dose with SBP and DBP in treated animals. Pearson’s correlation coefficient and P value are shown. (I) Kidney cGMP in each treatment group (n = 5/group) as measured by ELISA. Kruskal-Wallis was used to test the effect of each of the G5 doses compared to negative control GapmeR. *P < 0.05 after adjustment for multiple comparisons using Dunn’s test. For all graphs, mean and standard deviation are shown.
Coda Mouse Bp System, supplied by Kent Scientific Corp, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/coda+noninvasive+system/coda+noninvasive+system/pm41232443-62-11-15
Average 86 stars, based on 1 article reviews
coda mouse bp system - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
coda 8 channel high throughput noninvasive blood pressure system  (Kent Scientific Corp)
86
Kent Scientific Corp coda 8 channel high throughput noninvasive blood pressure system
(A) Schematic overview of the Nppa locus, including the natural antisense transcript Gm13054 on chromosome 4 (GRCm38/mm10 assembly). Arrows indicate direction of transcription. (B) Nppa-as and (C) Nppa expression in HL-1 cells transfected with different GapmeR designs and negative control, as measured by qRT-PCR. Expression is presented relative to Gapdh and normalized to the mean of the control group. Results are based on 3 separate experiments with 3 replicates in each group. Kruskal-Wallis was used to test the effect of each GapmeR design compared to the negative control. ***P < 0.001, **P < 0.01 after adjustment for multiple comparisons using Dunn’s test. (D) Nppa-as and (E) Nppa expression in atrial tissue of mice injected subcutaneously with 6.25, 12.5, or 25 mg/kg of GapmeR5 or 25 mg/kg of negative control GapmeR for 48 hours (n = 5–13 per group). Kruskal-Wallis was used to test the difference between animals treated with negative control and each of the G5 doses, as well as within G5 treatment groups. ***P < 0.001, *P < 0.05 after adjusting for multiple comparisons using Dunn’s test. (F) Plasma concentration of Anp in the saphenous vein of mice before and 48 hours after injection of the different Gapmer5 doses or 25 mg/kg of negative control GapmeR, as measured by ELISA (n = 5–13 per group). Repeated-measures 2-way ANOVA was used to test the difference before and after treatment in each group. *P < 0.05, **P < 0.01 after adjusting for multiple comparisons using Dunn’s test. (G) Systolic (SBP) and diastolic blood pressure (DBP) in mice before and 48 hours after GapmeR injections measured using a <t>noninvasive</t> <t>tail</t> <t>cuff</t> method (n = 5/group). Repeated-measures 2-way ANOVA was used to test for differences within groups. *P < 0.05 after adjusting for multiple comparisons using Dunn’s test. (H) Correlation of G5 dose with SBP and DBP in treated animals. Pearson’s correlation coefficient and P value are shown. (I) Kidney cGMP in each treatment group (n = 5/group) as measured by ELISA. Kruskal-Wallis was used to test the effect of each of the G5 doses compared to negative control GapmeR. *P < 0.05 after adjustment for multiple comparisons using Dunn’s test. For all graphs, mean and standard deviation are shown.
Coda 8 Channel High Throughput Noninvasive Blood Pressure System, supplied by Kent Scientific Corp, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/coda+noninvasive+system/8+blood+channel+coda+high+noninvasive+pressure+system+throughput/pm41166907-157-16-24
Average 86 stars, based on 1 article reviews
coda 8 channel high throughput noninvasive blood pressure system - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
coda high-throughput noninvasive blood pressure system  (NBT New Biotechnology Ltd)
90
NBT New Biotechnology Ltd coda high-throughput noninvasive blood pressure system
(A) Schematic overview of the Nppa locus, including the natural antisense transcript Gm13054 on chromosome 4 (GRCm38/mm10 assembly). Arrows indicate direction of transcription. (B) Nppa-as and (C) Nppa expression in HL-1 cells transfected with different GapmeR designs and negative control, as measured by qRT-PCR. Expression is presented relative to Gapdh and normalized to the mean of the control group. Results are based on 3 separate experiments with 3 replicates in each group. Kruskal-Wallis was used to test the effect of each GapmeR design compared to the negative control. ***P < 0.001, **P < 0.01 after adjustment for multiple comparisons using Dunn’s test. (D) Nppa-as and (E) Nppa expression in atrial tissue of mice injected subcutaneously with 6.25, 12.5, or 25 mg/kg of GapmeR5 or 25 mg/kg of negative control GapmeR for 48 hours (n = 5–13 per group). Kruskal-Wallis was used to test the difference between animals treated with negative control and each of the G5 doses, as well as within G5 treatment groups. ***P < 0.001, *P < 0.05 after adjusting for multiple comparisons using Dunn’s test. (F) Plasma concentration of Anp in the saphenous vein of mice before and 48 hours after injection of the different Gapmer5 doses or 25 mg/kg of negative control GapmeR, as measured by ELISA (n = 5–13 per group). Repeated-measures 2-way ANOVA was used to test the difference before and after treatment in each group. *P < 0.05, **P < 0.01 after adjusting for multiple comparisons using Dunn’s test. (G) Systolic (SBP) and diastolic blood pressure (DBP) in mice before and 48 hours after GapmeR injections measured using a <t>noninvasive</t> <t>tail</t> <t>cuff</t> method (n = 5/group). Repeated-measures 2-way ANOVA was used to test for differences within groups. *P < 0.05 after adjusting for multiple comparisons using Dunn’s test. (H) Correlation of G5 dose with SBP and DBP in treated animals. Pearson’s correlation coefficient and P value are shown. (I) Kidney cGMP in each treatment group (n = 5/group) as measured by ELISA. Kruskal-Wallis was used to test the effect of each of the G5 doses compared to negative control GapmeR. *P < 0.05 after adjustment for multiple comparisons using Dunn’s test. For all graphs, mean and standard deviation are shown.
Coda High Throughput Noninvasive Blood Pressure System, supplied by NBT New Biotechnology Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/coda+noninvasive+system/coda+high+throughput+noninvasive+blood+pressure+system/pm32243928-64-19-25
Average 90 stars, based on 1 article reviews
coda high-throughput noninvasive blood pressure system - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
coda high throughput noninvasive blood pressure system  (Kent Scientific Corp)
86
Kent Scientific Corp coda high throughput noninvasive blood pressure system
(A) Schematic overview of the Nppa locus, including the natural antisense transcript Gm13054 on chromosome 4 (GRCm38/mm10 assembly). Arrows indicate direction of transcription. (B) Nppa-as and (C) Nppa expression in HL-1 cells transfected with different GapmeR designs and negative control, as measured by qRT-PCR. Expression is presented relative to Gapdh and normalized to the mean of the control group. Results are based on 3 separate experiments with 3 replicates in each group. Kruskal-Wallis was used to test the effect of each GapmeR design compared to the negative control. ***P < 0.001, **P < 0.01 after adjustment for multiple comparisons using Dunn’s test. (D) Nppa-as and (E) Nppa expression in atrial tissue of mice injected subcutaneously with 6.25, 12.5, or 25 mg/kg of GapmeR5 or 25 mg/kg of negative control GapmeR for 48 hours (n = 5–13 per group). Kruskal-Wallis was used to test the difference between animals treated with negative control and each of the G5 doses, as well as within G5 treatment groups. ***P < 0.001, *P < 0.05 after adjusting for multiple comparisons using Dunn’s test. (F) Plasma concentration of Anp in the saphenous vein of mice before and 48 hours after injection of the different Gapmer5 doses or 25 mg/kg of negative control GapmeR, as measured by ELISA (n = 5–13 per group). Repeated-measures 2-way ANOVA was used to test the difference before and after treatment in each group. *P < 0.05, **P < 0.01 after adjusting for multiple comparisons using Dunn’s test. (G) Systolic (SBP) and diastolic blood pressure (DBP) in mice before and 48 hours after GapmeR injections measured using a <t>noninvasive</t> <t>tail</t> <t>cuff</t> method (n = 5/group). Repeated-measures 2-way ANOVA was used to test for differences within groups. *P < 0.05 after adjusting for multiple comparisons using Dunn’s test. (H) Correlation of G5 dose with SBP and DBP in treated animals. Pearson’s correlation coefficient and P value are shown. (I) Kidney cGMP in each treatment group (n = 5/group) as measured by ELISA. Kruskal-Wallis was used to test the effect of each of the G5 doses compared to negative control GapmeR. *P < 0.05 after adjustment for multiple comparisons using Dunn’s test. For all graphs, mean and standard deviation are shown.
Coda High Throughput Noninvasive Blood Pressure System, supplied by Kent Scientific Corp, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/coda+noninvasive+system/2+blood+coda+high+noninvasive+pressure+system+throughput/10__7554_slash_elife__91318-244-10-17
Average 86 stars, based on 1 article reviews
coda high throughput noninvasive blood pressure system - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

Image Search Results


(A) Schematic overview of the Nppa locus, including the natural antisense transcript Gm13054 on chromosome 4 (GRCm38/mm10 assembly). Arrows indicate direction of transcription. (B) Nppa-as and (C) Nppa expression in HL-1 cells transfected with different GapmeR designs and negative control, as measured by qRT-PCR. Expression is presented relative to Gapdh and normalized to the mean of the control group. Results are based on 3 separate experiments with 3 replicates in each group. Kruskal-Wallis was used to test the effect of each GapmeR design compared to the negative control. ***P < 0.001, **P < 0.01 after adjustment for multiple comparisons using Dunn’s test. (D) Nppa-as and (E) Nppa expression in atrial tissue of mice injected subcutaneously with 6.25, 12.5, or 25 mg/kg of GapmeR5 or 25 mg/kg of negative control GapmeR for 48 hours (n = 5–13 per group). Kruskal-Wallis was used to test the difference between animals treated with negative control and each of the G5 doses, as well as within G5 treatment groups. ***P < 0.001, *P < 0.05 after adjusting for multiple comparisons using Dunn’s test. (F) Plasma concentration of Anp in the saphenous vein of mice before and 48 hours after injection of the different Gapmer5 doses or 25 mg/kg of negative control GapmeR, as measured by ELISA (n = 5–13 per group). Repeated-measures 2-way ANOVA was used to test the difference before and after treatment in each group. *P < 0.05, **P < 0.01 after adjusting for multiple comparisons using Dunn’s test. (G) Systolic (SBP) and diastolic blood pressure (DBP) in mice before and 48 hours after GapmeR injections measured using a noninvasive tail cuff method (n = 5/group). Repeated-measures 2-way ANOVA was used to test for differences within groups. *P < 0.05 after adjusting for multiple comparisons using Dunn’s test. (H) Correlation of G5 dose with SBP and DBP in treated animals. Pearson’s correlation coefficient and P value are shown. (I) Kidney cGMP in each treatment group (n = 5/group) as measured by ELISA. Kruskal-Wallis was used to test the effect of each of the G5 doses compared to negative control GapmeR. *P < 0.05 after adjustment for multiple comparisons using Dunn’s test. For all graphs, mean and standard deviation are shown.

Journal: JCI Insight

Article Title: Antisense regulation of atrial natriuretic peptide expression

doi: 10.1172/jci.insight.130978

Figure Lengend Snippet: (A) Schematic overview of the Nppa locus, including the natural antisense transcript Gm13054 on chromosome 4 (GRCm38/mm10 assembly). Arrows indicate direction of transcription. (B) Nppa-as and (C) Nppa expression in HL-1 cells transfected with different GapmeR designs and negative control, as measured by qRT-PCR. Expression is presented relative to Gapdh and normalized to the mean of the control group. Results are based on 3 separate experiments with 3 replicates in each group. Kruskal-Wallis was used to test the effect of each GapmeR design compared to the negative control. ***P < 0.001, **P < 0.01 after adjustment for multiple comparisons using Dunn’s test. (D) Nppa-as and (E) Nppa expression in atrial tissue of mice injected subcutaneously with 6.25, 12.5, or 25 mg/kg of GapmeR5 or 25 mg/kg of negative control GapmeR for 48 hours (n = 5–13 per group). Kruskal-Wallis was used to test the difference between animals treated with negative control and each of the G5 doses, as well as within G5 treatment groups. ***P < 0.001, *P < 0.05 after adjusting for multiple comparisons using Dunn’s test. (F) Plasma concentration of Anp in the saphenous vein of mice before and 48 hours after injection of the different Gapmer5 doses or 25 mg/kg of negative control GapmeR, as measured by ELISA (n = 5–13 per group). Repeated-measures 2-way ANOVA was used to test the difference before and after treatment in each group. *P < 0.05, **P < 0.01 after adjusting for multiple comparisons using Dunn’s test. (G) Systolic (SBP) and diastolic blood pressure (DBP) in mice before and 48 hours after GapmeR injections measured using a noninvasive tail cuff method (n = 5/group). Repeated-measures 2-way ANOVA was used to test for differences within groups. *P < 0.05 after adjusting for multiple comparisons using Dunn’s test. (H) Correlation of G5 dose with SBP and DBP in treated animals. Pearson’s correlation coefficient and P value are shown. (I) Kidney cGMP in each treatment group (n = 5/group) as measured by ELISA. Kruskal-Wallis was used to test the effect of each of the G5 doses compared to negative control GapmeR. *P < 0.05 after adjustment for multiple comparisons using Dunn’s test. For all graphs, mean and standard deviation are shown.

Article Snippet: A noninvasive tail cuff system (CODA for rodents, emka Technologies) was used for BP measurements before and 48 hours after injection of GapmeR.

Techniques: Expressing, Transfection, Negative Control, Quantitative RT-PCR, Control, Injection, Clinical Proteomics, Concentration Assay, Enzyme-linked Immunosorbent Assay, Standard Deviation